Opinion|Videos|November 18, 2026

AATD Pipeline: Replacement, Liver-Directed, RNA, and Gene Therapy Approaches

AATD is drawing a wide range of mechanisms, from higher-dose and alternative-route replacement to correctors, RNA-based agents, and gene therapy, with liver-directed approaches now addressing disease that once had only transplantation.

"AATD Pipeline: Replacement, Liver-Directed, RNA, and Gene Therapy Approaches" follows Dr. Barjaktarevic through the full range of therapies in development over the next five years.

Dr. Haumschild asks Dr. Barjaktarevic how the pipeline will evolve over the next five years, noting that it includes gene therapy, inhaled AAT, RNA interference, and liver-targeted agents. Dr. Barjaktarevic says the field's enthusiasm reflects better identification of patients. He explains that AATD is a rare disorder that connects to one of the most common diseases, and it shows how much heterogeneity exists even when the genetics are known. That makes it a model for precision medicine.

He groups the approaches by strategy. Replacement comes first, including efforts to compare double and standard doses, with early signals that higher doses may help. Delivery is second, since a therapy could be inhaled to reach the lung directly or given subcutaneously, as is done with immunoglobulins. A third group lowers protease activity by targeting neutrophil elastase. A fourth uses small molecules as chaperones or correctors that stabilize the protein.

He then turns to the liver, which has long been neglected. Previously the options were education and, eventually, transplantation. New approaches aim to reduce polymer accumulation. RNA silencers, now in Phase 3 trials, reduce production of abnormal protein and therefore liver damage. RNA editing goes further by converting abnormal RNA into normal RNA. That raises normal protein while lowering abnormal protein, so it could address both liver and lung disease.

Gene therapy goes to the core by replacing or correcting the mutated gene. Gene therapies have been tested for 40 years, and progress is now nearly exponential. Researchers have moved from adenoviral and adeno-associated vectors to tools that can excise an abnormal base and restore normal messenger RNA. Some approaches are closer to approval, while longer-term options need safety and durability data. He expects these therapies to restore normal physiologic function, including higher gene expression during illness.

Up next, in "Payer Criteria for AATD: One-Time Therapies, Costs, and Matching Patients," Dr. Goldklang considers how payers may respond to one-time therapies and a growing list of formulary options.


Related to this article